원저 : 그레이브스 갑상선기능항진증 환자의 방사성옥소 ( 131I ) 치료시 실제 유효반감기의 측정 ( Measurements of Actual Effective Half - Life in 131I Therapy for Graves ` Hyperthyroidism ) () |
Author |
소용선(Yong Seon So),김명선(Myung Seon Kim),권기현(Ki Hyun Kwon),김석환(Seok Whan Kim),김태형(Tae Hyung Kim),한상웅(Sang Woong Han),김은실(Eun Sil Kim),김종순(Chong Soon Kim), |
|
Affiliation |
|
Abstract |
Radioiodine[131I] has been used for the treatment of
Graves' hyperthyroidism since the late 1940's and is
now generally regarded as the treatment of choice for
Graves' hyperthyroidism who does not remit following a
course of antithyroid drugs. But for the dose given,
several different protocols have been described by
different centers, each attempting to reduce the
incidence of long-term hypothyroidism while maintaining
an acceptable rate control of Graves' hyperthyroidism.
Our goals were to evaluate effective half-life and
predict absorbed dose in Graves' hyperthyroidism
patients, therefore, to calculate and readminister
radioiodine activity needed to achieve aimed radiation
dose. Our data showed that the mean effective 131I
half-life for Graves' disease is 5.3 days(S.D=0.88) and
mean biologic half-life is 21 days, range 9.5-67.2
days. The mean admininistered activity and the mean
values of absorbed doses wert: 532 MBq(S.D.=254), 112
Gy (S.D.=50.9), respectively. The mean activity needed
to achieve aimed radiation dose were 51 MBq and marked
differences of 131I thyroidal uptake between tracer and
therapy ocurred in our study. We are sure that the dose
calculation method that uses 5 days thyroidal 131I
uptake measurements after tracer and therapy dose,
provides sufficient data about the effective treatment
in Graves' hyperthyroidism |
Keyword |
Hyperthyroidism; Iodine-131; Effective half-life |
Full text Article |
28501625.pdf
|
|
|